Channel Therapeutics Corporation (CHRO)
| Market Cap | 3.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.07M |
| Shares Out | 6.03M |
| EPS (ttm) | -2.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 166,608 |
| Open | 0.646 |
| Previous Close | 0.653 |
| Day's Range | 0.586 - 0.650 |
| 52-Week Range | 0.450 - 6.000 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | n/a |
| Earnings Date | Nov 13, 2024 |
About CHRO
Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. The company was Chromocell Therapeutics Corporation and changed its name... [Read more]
Financial Performance
Financial StatementsNews
Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine
FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment thera...
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment thera...
Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates
FREEHOLD, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation, (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced th...
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain
FREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
Chromocell Announces Amendment to Stock Repurchase Plan
FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
Chromocell to Participate in Life Sciences Investor Forum September 19th
FREEHOLD, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatmen...
Chromocell Announces Stock Repurchase Plan
FREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
Chromocell to Participate in the Virtual Investor Lunch Break Series
Live webcast with Frank Knuettel II, Chief Executive Officer and Chief Financial Officer, on Thursday, July 18th at 12:00 PM ET Live webcast with Frank Knuettel II, Chief Executive Officer and Chief F...
Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024
FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment ...
Chromocell Issues Letter to Stockholders from Chief Executive Officer
FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatmen...
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment ther...
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment ther...
Chromocell to Present at Sidoti Virtual Investor Conference March 13-14
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment thera...
Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions
AUSTIN. Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp. (“Chromocell”), (NYSE American: CHRO), a ...
Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million
FREEHOLD, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell”, “our”, “us” or the “Company”), a clinical-stage biotech company focused on de...
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
FREEHOLD, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell” or the “Company”), a clinical-stage biotech company focused on developing and ...
IPO Update: Chromocell Therapeutics Seeks $8.7 Million In Micro-IPO
Chromocell Therapeutics Corporation has filed for an $8.7 million IPO to develop its treatment for chronic pain conditions. The company's lead compound is being prepared for a Phase 2a study for eryth...
Chromocell Therapeutics Seeks IPO For Erythromelalgia Treatment
Chromocell Therapeutics has filed to raise funding from a U.S. IPO. The firm is developing a drug candidate for the treatment of the chronic nerve pain erythromelalgia.
Chromocell Therapeutics Files for IPO
Chromocell Therapeutics Corp. filed for an initial public offering with the U.S. Securities and Exchange Commission on Wednesday.
Chromocell Therapeutics IPO Registration Document (S-1)
Chromocell Therapeutics has filed to go public with an IPO on the Nasdaq.